Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/31488385
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Neuromuscul Disord. 2019 Sep;29(9):664-670. doi: 10.1016/j.nmd.2019.07.006. Epub 2019 Jul 26.
Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.
de Meel RHP1, Tannemaat MR2, Verschuuren JJGM3.
The distribution of muscle weakness in myasthenia gravis (MG) patients with acetylcholine receptor (AChR) antibodies is highly variable.
As muscle groups respond differently to therapeutic interventions, it is important to acknowledge this variability.
We analysed the distribution of muscle weakness in 225 AChR MG patients over time.
On the basis of combinations of muscle weakness, seven phenotypes were defined: 'ocular' (O), 'bulbar' (B), 'neck/limbs/respiratory' (NLR), or a combination (O+B, O+NLR, B+NLR and O+B+NLR).
MG remained restricted to ocular weakness in 5%, whereas 7% never had ocular weakness.
At last follow-up, ocular or bulbar weakness had resolved more frequently than NLR weakness (40%, 38% and 25%; p = 0.003, respectively). Patients with O, B or OB phenotype at baseline had a higher age at onset and were more frequently male than patients with NLR, ONLR, BNLR or OBNLR phenotype (52.7 ± 17.5 vs. 44.0 ± 18.9; p = 0.007 and 64% vs. 37%; p = 0.002, respectively).
MG patients have heterogeneous distributions of muscle weakness and frequently shift between phenotypes.
The phenotypic variations found in AChR MG suggest that also other factors aside from the AChR antibody mediated immune response are of importance in determining the disease expression in MG.
Article intégral disponible pour nos donateurs